Role of PCSK9 inhibitors in the management of dyslipidaemia
Proprotein convertase subtilisin kexin9 (PCSK9) inhibitors are novel agents that lower LDL cholesterol and reduce cardio-vascular event rate. Being expensive, these agents are reserved for those with high risk or very high risk of CV events and with suboptimal response to statins and ezetimibe, with...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2024-03-01
|
| Seri Bilgileri: | Indian Heart Journal |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S0019483223004807 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|